Fig. 4

Change in DAS28-ESR and CDAI from baseline to weeks 4, 8, 12, 24, and 52. DAS28-ESR (A) improved in baricitinib 4 mg in the evening compared with baricitinib 4 mg in the morning at week 8. Similarly, CDAI (C) significantly improved in baricitinib 4 mg in the evening at weeks 4 and 8. Results are presented as the mean ± 95% confidence interval. (i) Baricitinib 2 mg in the morning vs. baricitinib 2 mg in the evening n = 50, 51, (ii) Baricitinib 4 mg morning vs. baricitinib 4 mg in the evening, n = 52, 53, respectively. Proportion of patients achieving (B) DAS28-ESR < 2.6, (D) CDAI ≤ 2.8 at weeks 12, 24, and 52. Baricitinib 4 mg in the evening has a higher rate of patients achieving DAS28 remission at weeks 12 and 24 and CDAI remission at weeks 12, 24, and 52. Error bars represented 95% confidence interval; n = 50, 51, 52, and 53 for baricitinib 2 mg in the morning, 2 mg in the evening, 4 mg in the morning, and 4 mg in the evening, respectively